A study of patients with T2D and NAFLD showed that the administration of OCA was well tolerated and generated an increase in insulin sensitivity and a reduction of markers of liver inflammation and fibrosis [35]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.